Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

BACKGROUND: The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel‐T immunotherapy for asymptomatic/minimally symptomatic metastatic castration‐resistant prostate cancer (mCRPC). METHODS: PROCEED enrolled...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Higano, Celestia S., Armstrong, Andrew J., Sartor, A. Oliver, Vogelzang, Nicholas J., Kantoff, Philip W., McLeod, David G., Pieczonka, Christopher M., Penson, David F., Shore, Neal D., Vacirca, Jeffrey, Concepcion, Raoul S., Tutrone, Ronald F., Nordquist, Luke T., Quinn, David I., Kassabian, Vahan, Scholz, Mark C., Harmon, Matt, Tyler, Robert C., Chang, Nancy N., Tang, Hong, Cooperberg, Matthew R.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6856402/
https://ncbi.nlm.nih.gov/pubmed/31483485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32445
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados